binimetinib
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium
The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.
Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.
Braftovi, Mektovi Approved in Europe for BRAF V600E-Mutant NSCLC
A Phase II trial of the combo demonstrated response rates of 75 percent and 46 percent in treatment-naïve and previously treated NSCLC patients, respectively.
Pfizer Reports Mixed Revenues for Oncology Products in Q4, Looks to Advancing Pipeline in 2024
Premium
With the completion of its acquisition of Seagen in December, the firm is aiming to become a leader in precision oncology.
Foundation Medicine, Pierre Fabre Laboratories to Collaborate on CDx for Lung Cancer
The companies will seek approval for Foundation Medicine's assays identifying patients for treatment with Pierre Fabre's BRAF/MEK inhibitor combination regimen.